Agonists of the nociceptin/orphanin FQ opioid peptide (NOP) receptor, a member of the opioid receptor family, are under active investigation as novel analgesics, but their modes of signaling are less well characterized than those of other members of the opioid receptor family. Therefore, we investigated whether different NOP receptor ligands showed differential signaling or functional selectivity at the NOP receptor. Using newly developed phosphositespecific antibodies to the NOP receptor, we found that agonist-induced NOP receptor phosphorylation occurred primarily at four carboxyl-terminal serine (Ser) and threonine (Thr) residues, namely, Ser
INTRODUCTION
The nociceptin/orphanin FQ peptide (NOP) receptor is the fourthdiscovered member of the opioid receptor family and is still the least characterized member (1) (2) (3) (4) . An endogenous neuropeptide identified from rat and porcine brain extracts was found to activate the NOP receptor by inhibiting cyclic adenosine monophosphate (cAMP) accumulation in transfected cells and was named nociceptin/orphanin FQ (N/OFQ) (5, 6) . Through coupling to G i /G 0 proteins, NOP receptor activation by N/OFQ leads to inhibition of adenylate cyclase and calcium channels (N-, L-, and P/Q-type), as well as the activation of G protein-coupled inwardly rectifying potassium (GIRK) channels (3, (6) (7) (8) (9) (10) (11) (12) (13) (14) . In addition, various proteins such as protein kinase C (PKC), phospholipase A2 (PLA2), extracellular signal-regulated kinase 1 (ERK1) and ERK2, p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK) are also activated by NOP receptors (12, (15) (16) (17) (18) (19) (20) . The NOP receptor is widely expressed throughout the brain, spinal cord, and dorsal root ganglia (DRG) (21) (22) (23) (24) (25) (26) and is involved in the regulation of important physiological processes, such as learning and memory, emotion, food intake, locomotion, respiration, and immune defense (6, (27) (28) (29) (30) (31) (32) (33) (34) (35) . NOP receptors are also involved in renal, cardiovascular, and gastrointestinal functions, as well as pain perception, addiction, and tolerance development (36) (37) (38) (39) (40) (41) .
The NOP receptor is under active investigation as a therapeutic drug target for many indications. Nonpeptidic, small-molecule NOP receptor agonists have been investigated preclinically as anxiolytics and substance abuse medications, and clinically as potential antitussives (42) . Being in the opioid receptor family, the NOP receptor has been shown to modulate the classical mu opioid (MOP) receptor pharmacology in pain and reward pathways. Intracerebroventricular N/OFQ administration can block morphine-, cocaine-, alcohol-, or methamphetamine-induced rewarding effects, as well as increases in extracellular dopamine in mesolimbic pathways (43) (44) (45) (46) (47) (48) . Novel analgesics with bifunctional activity targeting the MOP and NOP receptors have been developed, one of which is in clinical trials (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) . Cebranopadol, the first bifunctional MOP/NOP receptor agonist to reach phase 3 clinical trials for acute and chronic pain, has potent antinociceptive activity in rodent pain models and is ~1000 times more potent and longer lasting than morphine in chronic pain assays (59, 61) . Cebranopadol exhibited a reduced side-effect profile including development of tolerance, motor deficits, or respiratory depression compared with classical MOP receptor agonists (58) (59) (60) (61) (62) (63) (64) . AT-121, a MOP/NOP receptor bifunctional ligand with partial agonist activity at both receptors, was reported to show morphinecomparable analgesic effects in nonhuman primates, and no side effects such as respiratory depression, abuse potential, and physical dependence (65) .
Given the global opioid epidemic, alternatives and approaches to decrease the side effects of classical opioid-based drugs have focused on biased ligands, which preferentially activate the G proteindependent signaling cascades over the G protein-independent signaling, such as arrestin-mediated signaling (66) (67) (68) (69) . This differential activation was found to lead to a dissociation of analgesic effects from adverse effects such as respiratory depression, gastrointestinal effects, and tolerance, the former considered a G protein-mediated effect (analgesic efficacy) and the latter (undesired effects) due to arrestin recruitment. These correlations form the fundamental basis for the development of the biased MOP receptor agonist TRV130 that recently completed phase 3 clinical trials (69) (70) (71) (72) (73) (74) . TRV130 is "biased" for the G protein-mediated pathway over the arrestin pathway and shows markedly reduced receptor internalization and arrestin recruitment (75, 76) .
The clinical use of drugs targeting NOP receptors requires a profound understanding of the NOP receptor system at the physiological and molecular levels. However, much less is understood about NOP receptor signaling after ligand binding. A report by Chang et al. (77) showed that various NOP receptor agonists had differential efficacy in activating G protein-dependent cAMP inhibition compared to G protein-independent arrestin recruitment, leading to functional selectivity or "signaling bias." Similarly, other studies demonstrated that the NOP receptor partial agonist AT-090 showed arrestin-biased functional selectivity in recombinant cells (78) . The detailed molecular events occurring after ligand binding that lead to signaling bias at the NOP receptor are not as yet completely unraveled. In particular, key events in the regulation of G protein-coupled receptors (GPCRs) such as receptor phosphorylation, internalization, and desensitization that have been characterized in great detail for the classical opioid GPCRs are not well understood for the NOP receptor (79) (80) (81) (82) (83) (84) (85) . For example, in the closely related MOP receptor, a cluster of four C-terminal serine (Ser) and threonine (Thr) residues, namely, Ser , is phosphorylated by GPCR kinases 2 and 3 (GRK2/3) as well as GRK5 in an agonistselective and hierarchical manner (86) (87) (88) . Our own studies with the MOP receptor show that its phosphorylation and internalization occurs in an agonist-specific and time-dependent manner and is determined by a 10-residue sequence in the C-terminal tail of the receptor. Ser 375 , present in the middle of this sequence, is phosphorylated by many opioids. Morphine, oxycodone, and buprenorphine stimulate phosphorylation only at Ser 375 , and the morphine-induced phosphorylation is mediated by GRK5 (86) (87) (88) (88) . In the case of the NOP receptor, it is known that GRK2 and GRK3 are relevant for NOP receptor desensitization (89) (90) (91) . In addition, GRK3 and b-arrestin2 appear to be important for N/OFQ-induced internalization, because point mutation of Ser 363 reduces, but not completely blocks, NOP receptor internalization (12) . It is possible that several phosphorylation sites are essential for internalization and desensitization of the NOP receptor. Further, given the differential functional selectivity among chemically diverse reported NOP receptor agonists, it is possible that different agonists may induce recruitment of one or more GRK isoforms to the NOP receptor. Here, we investigated the mechanisms of agonist-induced NOP receptor phosphorylation by generating and extensively characterizing the first phosphosite-specific antibodies for the NOP receptor C (Fig. 1A) . In whole-cell phosphorylation assays, we observed a robust increase in NOP receptor phosphorylation after addition of its endogenous ligand N/OFQ (Fig. 1B) . This increase was not observed in a NOP receptor mutant (6S/T-A), in which all six C-terminal serine and threonine residues were exchanged to alanine (Fig. 1B) . This finding suggests that agonist-induced NOP receptor phosphorylation occurs primarily within its C-terminal tail. In an effort to examine the temporal and spatial dynamics of NOP receptor phosphorylation, we generated polyclonal phosphosite-specific antibodies for the C-terminal residues Ser 346 , Ser 351 , and Thr 362 /Ser 363 (Fig. 1A) . In addition, we also generated a polyclonal phosphorylation-independent antibody to the NOP receptor (Fig. 1A) . First, antisera were affinitypurified against their immunizing peptides, and specificity was then verified with synthetic phosphopeptides and corresponding nonphosphopeptides using dot-blot assays (Fig. 1C) . All antibodies, which detected their respective peptide without cross-reaction with the nonphosphopeptide, were further characterized using Western blot analysis. (Fig. 1, D and E). After treatment with -phosphatase, all phosphosite-specific antibodies were no longer able to detect their cognate forms of phosphorylated NOP receptors, whereas the receptor protein was still detectable using the phosphorylationindependent NOP receptor antibody (Fig. 1, D and E) .
For further characterization of the phosphosite-specific antibodies, different NOP receptor mutants were generated ( Fig. 2A) . As expected, receptor phosphorylation was not detectable after global mutation of all serine and threonine residues present in the C-terminal tail (6S/T-A) or in a mutant with additional mutation of all serine and threonine residues within the third intracellular loop (10S/T-A). No phosphorylation signal for pSer 346 and pSer 351 was detectable in the S337A/S346A/S351A mutant (Fig. 2 , B and C, left columns). Conversely, receptor constructs with a T362A/S363A/T365A mutation and an S363A point mutation displayed no binding of the anti-pThr 362 /pSer 363 antibody after N/OFQ stimulation (Fig. 2B, middle column) . It should be noted that the phosphorylation-independent NOP receptor antibody was not able to detect any protein band corresponding to the mutant construct T362A/S363A/T365A, suggesting that this sequence may contribute to the epitope recognized by the antibody (Fig. 2B, right column). Probing for the hemagglutinin (HA) epitope tag ensured that the T362A/S363A/T365A construct was expressed, as well as all other NOP receptor constructs used in this study (Fig. 2, B (Fig. 3, A and B (Fig. 3, C and D) . The time course of NOP receptor internalization was visualized by fluorescence microscopy and quantified using a cell surface enzyme-linked immunosorbent assay (ELISA). NOP receptor internalization was first detectable after 5 min and reached a maximum after 60 min of agonist treatment (Fig. 3, E (Fig. 4, A and B) . Treatment with specific GRK2 or GRK3 siRNA sequences also led to a significant reduction of N/OFQ-induced phosphorylation of these residues (Fig. 4C and fig. S1A ). Given the close relationship between GRK2 and GRK3, it is possible that the loss of one isoform could be compensated for by the other isoform. Therefore, we evaluated the inhibitory effect of siRNA knockdown of both GRK2 and GRK3. Combined siRNA knockdown of both GRK isoforms produced a stronger inhibition of Ser ( Fig. 4C and fig. S2A ). To confirm these results, we performed GRK2 and GRK3 plasmid overexpression experiments. As expected, overexpression of GRK2 or GRK3 strongly enhanced N/OFQ-induced Ser (Fig. 4D and fig.  S1B ). These results suggest that GRK2 and GRK3 are responsible for N/OFQ-induced NOP receptor phosphorylation.
Chemically diverse small-molecule NOP receptor agonists induce varying amounts of NOP receptor phosphorylation and internalization
We next examined a range of chemically diverse NOP receptor ligands for their ability to induce NOP receptor phosphorylation and internalization. We consistently observed that the endocytotic activity of these agonists was associated with their ability to induce receptor phosphorylation at Ser 346 , Ser 351 , and Thr 362 /Ser 363 ( 
Chemically diverse NOP receptor agonists show varying levels of functional efficacies in GIRK channel activation (G protein-dependent signaling)
To analyze G protein signaling of the NOP receptor at high temporal resolution, we used a previously described fluorescence-based membrane potential assay that detects Gb-dependent activation of inwardly rectifying potassium (GIRK) channels (92) . AtT-20 cells, a mouse pituitary tumor cell line, stably transfected with the NOP receptor S4D ). Collectively, these results indicate that NOP receptors can couple to GIRK channels endogenously expressed in AtT-20 cells. Next, we evaluated the ability of a variety of NOP receptor ligands to activate GIRK channels (Fig. 6 , A to G). MCOPPB was the most potent agonist tested with an EC 50 of 0.06 ± 0.02 nM compared to N/OFQ (EC 50 of 1.5 ± 0. 
NOP receptor antagonists selectively inhibit N/OFQ-induced phosphorylation and internalization in vitro
The opioid receptor antagonist naloxone did not inhibit NOP receptor phosphorylation or internalization after N/ OFQ treatment (Fig. 7, A to D ). In contrast, the selective NOP receptor antagonists J-113397 and SB 612111 (93, 94) (Fig. 7, A and B) . J-113397, but not naloxone, was also able to block N/OFQinduced internalization (Fig. 7, C and D) . Only selective NOP receptor antagonists could inhibit N/OFQ-induced phosphorylation and internalization.
NOP receptor phosphorylation is also observed in vivo after systemic treatment with NOP receptor agonists Using the phosphorylation-independent NOP receptor antibodies, we analyzed NOP receptor tissue distribution using Western blot. We were able to detect the NOP receptor in the brain, spinal cord, and DRG, but not in the lung, heart, bladder, kidney, and adrenal gland (Fig. 8A) . . Blots were stripped and reprobed for the NOP receptor. Densitometry, above the blots, was normalized to those in SCR-or MOCK-transfected cells, which were set to 100%. Data are means ± SEM from five to six independent experiments. *P < 0.05 versus SCR or MOCK by one-way analysis of variance (ANOVA) with Bonferroni post-test.
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For in vivo analysis of NOP receptor phosphorylation, the nonpeptide full agonist AT-202 was administered by intraperitoneal injection to three mice. This NOP receptor agonist allows for systemic administration with statistically significant central bioavailability (50, 54, 95) . Several peptides from the third transmembrane helix and the C-terminal part of the mouse NOP receptor were identified by 
analysis (Fig. 8, B and C). The 339 EMQVSDRVR 347 peptide containing Ser 343 was found only in its phosphorylated form in both saline-and AT-202-treated samples (Fig. 8D) (Fig. 9B and fig. S5A ) and could be blocked by the NOP receptor-selective antagonist SB 612111 (Fig. 9C and fig.  S5B ). To evaluate the in vivo contribution of GRKs to AT-202-induced NOP receptor phosphorylation, we used the selective GRK2/3 inhibitor (Fig. 9D) . These results suggest that GRK2 and GRK3 are also responsible for AT-202-induced NOP receptor phosphorylation in vivo. AT-202, Ro64-6198, and SCH221510, but not NNC 63-0532, induced strong NOP receptor phosphorylation at (Fig. 9, E to G, and fig. S5C ). Only a weak escalation of phosphorylation signal was detectable after administration of the NOP receptor agonist MCOPPB, in comparison to the treatment with saline at Ser 348 (equivalent in human S351) and Thr (Fig. 9E  and fig. S5C ). In contrast, there was a strong MCOPPB-induced NOP receptor internalization and phosphorylation signal at Ser 343 (equivalent in human Ser
346
) detectable (Fig. 9, E to G, and fig. S5C ). Moreover, addition of the NOP receptor antagonist J-113397 blocked the N/OFQ-induced internalization (Fig. 9, F and G) . These results indicate that the NOP receptor phosphorylation and internalization occurs in an agonist-selective manner.
DISCUSSION
Using the first phosphosite-specific antibodies for the NOP receptor, we found evidence for hierarchical and temporally controlled multisite phosphorylation of NOP receptors, both in vitro and in vivo. Moreover, we detected distinctive ligandselective phosphorylation patterns. The canonical model for GPCR activation/ deactivation cycle postulates the following steps: The agonist-bound receptor/G protein complex becomes a substrate for GRKs or second messenger-dependent protein kinases. Phosphorylation by GRKs increases the affinity for b-arrestins, which uncouple the receptor from its G protein and target it to clathrin-coated pits for internalization, thus desensitizing the primary signaling while simultaneously initiating b-arrestin-dependent signaling. Internalized GPCRs either are trafficked to lysosomes for degradation or recycle back through an endosomal pathway.
Agonist-induced phosphorylation has been studied in great detail for several GPCRs, most notably b2-adrenoceptor (b2-AR), MOP receptor, somatostatin sst2, sst3, and sst5 receptor subtypes, and angiotensin II AT1a receptors (86) (87) (88) (96) (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) (107) (108) . The emerging picture obtained from these studies suggests that the endogenous agonist N/OFQ induces phosphorylation that proceeds in a temporal hierarchy, involving multiple serine and threonine residues located in the C-terminal domain of the NOP receptor. In each GPCR case, a primary phosphate-acceptor site has been identified and phosphorylation levels positively correlate with receptor internalization (C) HEK293 cells stably expressing the NOP receptor were preincubated with antibody to HA-tag and then treated with vehicle (DMSO), 50 M naloxone, J-113397, or SB 612111 and with or without 10 M N/OFQ for 60 min at 37°C. Cells were then fixed and labeled with a peroxidase-conjugated secondary antibody, and receptor internalization was measured by ELISA and quantified as percentage of internalized receptors in agonist-treated cells. Data are means ± SEM from six independent experiments performed in quadruplicate. *P < 0.05 versus N/OFQ by one-way ANOVA with Bonferroni post-test. (D) Cells described and treated as in (C), except treated at 22°C, were fixed, permeabilized, immunofluorescently stained, and examined using confocal microscopy. Images are representative of one of three independent experiments. Scale bar, 20 m. levels. In contrast, many synthetic agonists were found to produce only partial receptor phosphorylation, combined with reduced agoniststimulated internalization. These observations support the general hypothesis that exhaustive GPCR phosphorylation is a prerequisite for internalization and a hallmark of full agonists.
For /Ser 363 phosphorylation is also predominantly mediated by GRK2/3. Nevertheless, a function of GRK5/6 in NOP receptor regulation and signaling cannot be ruled out.
Similar to MOP receptor agonists (86) (87) (88) , most synthetic NOP receptor agonists displayed reduced potencies to stimulate receptor phosphorylation, which appeared to correlate with the level of agonistinduced internalization. One notable exception is MCOPPB, which has been described as 10-fold more potent than N/OFQ in inhibiting cAMP accumulation and displaying strong G protein-biased signaling (77, 109) . Our results from GIRK channel activation assay support these previous findings. MCOPPB was also the only synthetic agonist that exhibited similar potency as N/OFQ to induce NOP receptor phosphorylation in vitro. NOP receptor agonists SCH221510 and Ro64-6198 have been previously described as full agonists in G protein-dependent cAMP assay (55, 77) . We confirmed these results with our study. Agonist AT-202 was described as a modestly selective NOP receptor full agonist, with very low efficacy at the MOP receptor (54) . In our GIRK channel activation assay, we confirmed that AT-202 acted as a NOP receptor full agonist. In contrast, the small-molecule NOP receptor agonist NNC 63-0532 failed to induce any phosphorylation at the NOP receptor, but behaved as a full agonist in G protein-mediated GIRK channel activation, albeit with about 40-fold reduced potency compared to N/OFQ. The opioid agonist buprenorphine, which also shows low agonist efficacy at the NOP receptor (66, (110) (111) (112) (113) (114) , displayed partial agonism in G protein-mediated GIRK assay. NNC 63-0532 and buprenorphine had previously been described as partial agonists at the NOP receptor in cAMP inhibition assays (77) . The same study revealed an almost complete absence of b-arrestin recruitment, which is consistent with the complete lack of NOP receptor phosphorylation by both agonists. Morphine and fentanyl are the most effective drugs for the treatment of severe pain. However, severe side effects, misuse of opioids, and opioid addiction limit their use in clinical setting so that the development of addiction-free effective opioids for treating severe pain is required. Cebranopadol is the first bifunctional MOP/NOP receptor agonist that is in advanced clinical trials for the treatment of acute and chronic pain (58, 59 ) and has previously been described as full agonist in calcium mobilization and bioluminescence resonance energy transfer (BRET) studies (62) as well as in guanosine 5′-O-(3′-thiotriphosphate) (GTP--S) assays (59) . In our phosphorylation studies as well as the GIRK channel activation assay, cebranopadol behaved as partial agonist at the NOP receptor. AT-121 is another bifunctional partial agonist at the MOP/NOP receptor that is able to suppress oxycodone-induced reinforcing effects and elicit morphine-like analgesic effect without common side effects of classical opioids (65) . Full NOP receptor agonists such as Ro64-6198 or AT-202 often induce a strong decrease in locomotor activity in vivo, which limits their clinical utility (50, 115) . Both cebranopadol and AT-121 are devoid of this activity, suggesting that partial agonism may be a desired property for the development of bifunctional MOP/NOP receptor ligands as effective painkillers with fewer side effects.
Localization of the NOP receptor has been characterized using in vitro autoradiography, in situ hybridization, and immunofluorescence staining (1-3, 22-26, 116-119 and Ser 348 are constitutively phosphorylated in the absence of agonist. This basal phosphorylation may reflect high constitutive activity of the NOP receptor. Nevertheless, after agonist injection, an increase of phosphorylation at both these sites was also observed. AT-202-induced phosphorylation occurred in a dose-dependent manner and could be blocked with SB 612111. In accordance with the corresponding human phosphorylation sites, in vivo phosphorylation in mice occurred in an agonist-selective manner, similarly to the MOP receptor (101 (101) . NOP receptor internalization in vivo also occurred in an agonist-dependent manner and could be blocked by J-113397.
In conclusion, we identified an agonist-selective phosphorylation pattern in the C-terminal domain of the NOP receptor in vitro and in vivo that correlates with receptor internalization. It is conceivable that the selective phosphorylation patterns provide an indication of a general biochemical mechanism by which the different functional effects of N/OFQ might be explained. Further, differential phosphorylation patterns among nonpeptidic NOP receptor agonists suggests that structure-function correlations may be possible for the NOP receptor and may explain the differences in NOP receptor agonist pharmacology. This study provides important tools to characterize agonist-dependent regulation of NOP receptor signaling at the cellular level, which may be beneficial for the development and characterization of NOP receptor agonists for therapeutic indications.
MATERIALS AND METHODS

Animals
NOP-eGFP mice (8 to 12 weeks old) were used to detect NOP receptor phosphorylation in vivo. Animals were group-housed under standard laboratory conditions and kept on a 12-hour day/night cycle (lights on at 7:00 a.m.) at constant temperature (20°C to 22°C) and humidity (45% to 55%) with ad libitum access to food and water. Animals were handled three times before the experiment. Mice were maintained in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and the Thuringian state authorities and complied with European Commission regulations for the care and use of laboratory animals. All methods used were preapproved by the Institutional Animal Care and Use Committee at the Torrey Pines Institute for Molecular Studies (Port St. Lucie) and the University Hospital Jena, Institute of Pharmacology and Toxicology (Jena).
NOPR-eYFP mice were used to detect NOP receptor internalization in primary neurons. For these mice, eYFP (enhanced yellow fluorescent protein) was knocked into exon 4 of the NOP receptor and fused at the C terminus of the receptor, flanked on both sides by loxP sites. Embryonic mice were removed from euthanized pregnant female mice on gestational day 14 (E14) and used for ventral midbrain dissection. All procedures were approved by the Animal Care and Use Committee of Washington University and adhered to NIH guidelines.
Plasmids
DNA for the hNOP receptor and hNOP receptor mutants was generated via artificial synthesis and cloned into pcDNA3.1 by imaGenes and Eurofins, respectively. The coding sequence for an N-terminal HA-tag was added. Human GRK2 and GRK3 plasmids were obtained from OriGene and transOMIC, respectively.
Antibodies
Peptide sequences used for generating phosphosite-specific antibodies against individual phosphorylated forms of the NOP receptor are shown in Table 1 , including a phosphorylation-independent antiserum targeting a distal epitope in the NOP receptor C-terminal domain. The respective peptides were coupled to keyhole limpet hemocyanin after high-performance liquid chromatography purification. The conjugates were mixed 1:1 with Freund's adjuvant and injected into groups of two or three rabbits (5033 and 5034) for antipSer 346 antibody production, (4876 and 4878) for anti-pSer 351 antibody production, (4873 to 4875) for anti-pThr 362 /Ser 363 antibody production, and (4870 to 4872) for anti-NOP receptor antibody production. The rabbits were injected at 4-week intervals, and serum was obtained 2 weeks after immunizations, beginning with the second injection. Using dot-blot analysis, specificity of the antisera was tested. For subsequent analysis, antibodies were affinity-purified against their immunizing peptide, immobilized using the SulfoLink kit (Thermo Fisher Scientific). Generation and characterization of the polyclonal rabbit anti-HA antibody was previously described (121) . Anti-GRK2 (sc-562), anti-GRK3 (sc-563), and anti-rabbit immunoglobulin G (IgG) horseradish peroxidase (HRP)-coupled (sc-2004) antibodies were obtained from Santa Cruz Biotechnology. The anti-HA IgG CF 488A antibody (SAB4600054) was purchased from Sigma-Aldrich. Anti-rabbit Alexa 488-coupled antibody (A11008) was obtained from Invitrogen.
Drugs
The NOP receptor agonist AT-202 was synthesized and provided by Astraea Therapeutics. Ro64-6198 was provided by Roche. Nociceptin (ab120070) and dynorphin A (ab120412) were obtained from Abcam. MCOPPB (PZ0159), b-endorphin (E6261), DADLE (E7131), DAMGO (E7384), etonitazene (E5007), etorphine, fentanyl (F3886), hydromorphone (H5136), [Met]-enkephalin (M6638), morphine-6-glucuronide (M3528), oxycodone (O1378), pentazocine (P134), tapentadol (T058), naloxone (N7758), and PMA (P8139) were purchased from SigmaAldrich. SCH221510 (3240), NNC 63-0532 (1780), J-113397 (2598), SB 612111 (3573), DPDPE (1431), endomorphin-1 (1055), endomorphin-2 (1056), U50488 (0495), PTX (3097), SCH23390 (0925), and forskolin (1099) were obtained from Tocris. Norbuprenorphine (BUP-982-FB) and buprenorphine (BUP-399-HC) were purchased from Lipomed. -Endorphin (60893-02-9) was obtained from Bachem, and tramadol was obtained from Grunenthal. Levomethadone (00424906) and pethidine (03012446) were purchased from Sanofi-Aventis. Morphine (26-6) was obtained from Merck Pharma. Nalfurafine (A12579) was purchased from AdooQ Bioscience LLC. Piritramid and sufentanil were obtained from Hameln Pharma Plus. Remifentanil was purchased from GlaxoSmithKline. Nortilidine was obtained from Pfizer AG. Cebranopadol (HY-15536) was purchased from MedChem Express. -Phosphatase (P0753S) was obtained from Santa Cruz Biotechnology. Compound 101 (HB2840) was obtained from Hello Bio. Tertiapin-Q was purchased from Alomone Labs. AT-202, Ro64-6198, PMA, SCH221510, NNC 63-0532, J-113397, SB 612111, DPDPE, U50488, forskolin, nalfurafine, and cebranopadol are DMSO soluble, and all the other mentioned compounds are water soluble.
Cell culture and transfection HEK293 cells were obtained from the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen). AtT-20/D16v-F2 (AtT-20) cells were purchased from the American Type Culture Collection. All cells were cultured at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum, 2 mM l-glutamine, and penicillin/streptomycin (100 U/ml). HEK293 and AtT-20 cells were stably transfected with TurboFect (Thermo Fisher Scientific). Stable transfected cells were selected in medium supplemented with geneticin (400 g/ml).
Fluorescence-activated cell sorting
To increase the number of HEK293 cells or AtT-20 cells stably expressing the hNOP receptor or mutant hNOP receptors, fluorescence-activated cell sorting (FACS) was used. Cells were incubated with trypsin, washed with phosphate-buffered saline (PBS), resuspended in Opti-MEM containing anti-HA IgG, CF 488 antibody (Sigma-Aldrich), and incubated for 30 min at room temperature. Again, cells were centrifuged and resuspended in FACS buffer [1 mM EDTA, 25 mM Hepes (pH 7.0), 1% bovine serum albumin (BSA) in PBS without Ca 2+ and Mg 2+ ]. Subsequently, cells were strained (strainer, 40 m). Transfected cells were sorted using a FACSAria III cell sorter (488-nm argon laser, BD Biosciences) and thereafter recultivated as described. This process was repeated two to three times to increase enrichment of stably transfected cells. Table 1 . NOP receptor peptide sequences used for generation of phosphosite-specific antisera. List of peptide sequences used for generating phosphosite-specific antibodies against individual phosphorylated forms of the NOP receptor and a phosphorylationindependent antiserum targeting the NOP receptor at the end of the C-terminal domain. Endogenous cysteines were exchanged (abu).
Antiserum name
Sequence used for immunization siRNA silencing of gene expression Chemically synthesized double-stranded siRNA duplexes (with 3′-dTdT overhangs) were obtained from Qiagen for the following targets: GRK2 (5′-AAGAAAUUCAUUGAGAGCGAU-3′) and GRK3 (5′-AAGCAAGCUGUAGAACACGUA-3′), and a non-silencing RNA duplex (5′-GCUUAGGAGCAUUAGUAAA-3′ and 3′-UUUACUAAUG-CUCCUAAGC-5′) was obtained from GE Dharmacon. Stably HA-hNOP receptor-expressing HEK293 cells were transfected with 150 nM siRNA for single transfection or with 100 nM of each siRNA for double transfection for 3 days using HiPerFect. All experiments showed target protein abundance reduced by ≥80%.
Amino acid position in hNOP receptor
Whole-cell phosphorylation assays
Phosphorylation studies were carried out as described (121) (122) (123) 4) , 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 10 mM disodium pyrophosphate, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS] in the presence of protease and phosphatase inhibitors cOmplete mini and PhosSTOP (Roche Diagnostics) and solubilized. HA-tagged hNOP receptors were immunoprecipitated using 50 l anti-HA agarose beads (Thermo Fisher Scientific), and receptors were eluted in SDS sample buffer for 30 min at 50°C. Samples were size-separated on 7.5% SDS-polyacrylamide gels followed by autoradiography.
Western blot analysis
Stably transfected cells were plated onto poly-l-lysine-coated 60-mm dishes and grown for 2 days to 80% confluency. After treatment with agonists or antagonists, cells were lysed with detergent buffer [50 mM tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 10 mM disodium pyrophosphate, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS] in the presence of protease and phosphatase inhibitors. Where indicated, cells were preincubated with GRK2/3 inhibitor compound 101 or NOP receptor antagonists for 30 min before agonist exposure. After 30-min centrifugation at 4°C, HA-tagged hNOP receptors were enriched using anti-HA agarose beads. Samples were inverted for 1.5 hours at 4°C. Where indicated, samples were dephosphorylated with -protein phosphatase (Santa Cruz Biotechnology) for 1 hour at 30°C. After washing, proteins were eluted using SDS sample buffer for 30 min at 50°C. Proteins were separated on 7.5% or 12% SDS-polyacrylamide gels, and after electroblotting, membranes were incubated with antibodies (0.1 g/ml) to pSer 346 (4874) overnight at 4°C, followed by detection using ECL detection of bound antibodies (Thermo Fisher Scientific). Blots were subsequently stripped and reprobed with the phosphorylation-independent antibody to the NOP receptor (4871) or antibody to HA-tag (0631) to ensure equal loading of the gels.
In vivo phosphorylation studies
First, the distribution of the NOP receptor in NOP-eGFP mouse brain and periphery was examined. Briefly, mice (n = 3) were euthanized under deep anesthesia and organs (brains, spinal cord, DRG, lungs, heart, kidneys, and adrenal glands) were collected, flash-frozen on dry ice, and stored at −80°C until biochemical analysis. In a second set of experiments, the ability of different NOP receptor agonists to induce NOP receptor phosphorylation in vivo was investigated. /Ser 363 (4874) at a concentration of 0.1 g/ml, followed by ECL detection of bound antibodies. Blots were stripped and reprobed with the phosphorylation-independent antibody to the NOP receptor (4871) or antibody to GFP (Synaptic Systems) to confirm equal loading of the gels.
Analysis of NOP receptor internalization
Stably transfected HA-tagged hNOP receptor cells or receptor mutant cells were plated onto poly-l-lysine-coated coverslips and grown overnight. Cells were incubated with rabbit anti-HA antibody (0631) in serum-free medium for 2 hours at 4°C. After agonist or antagonist exposure for 60 min at room temperature, cells were fixed with 4% paraformaldehyde and 0.2% picric acid in phosphate buffer (pH 6.9) for 30 min at room temperature. Subsequently, cells were washed several times with phosphate buffer [1 M NaH 2 PO 4 •H 2 O (22.6 ml/liter), 1 M Na 2 HPO 4 •H 2 O (77.4 ml/liter), and 0.1% Triton X-100 (pH 7.4)], permeabilized, and then incubated with an Alexa 488-coupled goat anti-rabbit antibody (Invitrogen). Cells were mounted, and internalization was examined using a Zeiss LSM 510-META Confocal laser scanning microscope. For quantitative internalization assays, cells were plated onto 24-well plates and grown overnight. Cells were preincubated with anti-HA antibody (0631) for 2 hours at 4°C and then exposed to agonists or antagonists for 60 min at 37°C. Subsequently, cells were fixed for 45 min at room temperature, washed three times with PBS, and incubated with a peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology). After washing, ABTS [2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt] substrate was added and optical density was measured at 405 nm using a FlexStation 3 microplate reader (Molecular Devices).
Primary culture of ventral midbrain neurons
Ventral midbrain neurons were cultured using a procedure adapted from (124) . The ventral mesencephalon was removed from embryonic day 14 (E14) NOPR-eYFP mice. Tissues were mechanically dissociated, incubated with 0.25% trypsin and 0.05% deoxyribonuclease in Dulbecco's PBS for 20 min at 37°C, and triturated using ART 200 REACH Barrier pipette tips (Thermo Fisher Scientific). Glass-bottom dishes (Cellvis) were precoated overnight with poly-d-lysine (2 mg/ml), then rinsed three times with sterile water, and dried before use on the day of dissections. Trituration and initial plating were performed in DMEM+ [DMEM/F12 with Hepes, supplemented with 10% fetal bovine serum, 1× B27 additive, glucose (1 g/ml), and 1× penicillinstreptomycin]. Dissociated neurons were diluted to 1 million cells/ml in DMEM+ and plated as a 50-l drop in the center well of the glassbottom dishes. The dishes were incubated for 1 hour at 37°C, 5% CO 2 to let the cells adhere, and then 2 ml of a 2:1 solution of DMEM+/ NB+ was added to the dish (NB+: neurobasal medium supplemented with B27 additive, 1× penicillin/streptomycin, and l-glutamine). Every 2 to 3 days, one-half of the medium was replaced with NB+.
NOP receptor internalization studies in primary ventral midbrain neurons
Dissociated cultures of ventral midbrain neurons from NOPR-eYFP mice were imaged at 7 to 10 days in vitro using an Andor Revolution imaging system consisting of a Leica DMI6000 B microscope, a Yokogawa CSU-X1 spinning disk unit, an Andor iXon electron-multiplying charge-coupled device camera, and a laser combiner with four solidstate lasers, all controlled using Andor iQ3 software. All imaging was performed inside a temperature-controlled chamber held at 37°C, 5% CO 2 . Images were acquired using a 63× oil immersion objective, 515-nm laser excitation, and 8-s exposure time.
Membrane potential assay
Membrane potential was measured as previously described (92 , and 20 l of the compound was added to the cells, resulting in a final volume in the well of 200 l and a 1:10 dilution of the compound. Hence, the compounds were prepared at 10× concentrations. A baseline reading is measured for 60 s before compounds or buffer was injected. Measurements were accomplished at 37°C using a FlexStation 3 microplate reader (Molecular Devices). The data were first normalized to the baseline and then subtracted from the buffer-only trace for each corresponding data point.
NanoLC-MS/MS analysis
After intraperitoneal administration of saline or AT-202 (30 mg/kg) and GFP immunoprecipitation from three brains per condition, immunoprecipitates were boiled in SDS sample buffer for 5 min at 100°C. Subsequently, brain extracts were alkylated in 90 mM iodoacetamide for 30 min in the dark, separated by SDS-PAGE on 10% polyacrylamide gels, followed by gel staining with colloidal Coomassie blue. At the molecular weight of the NOP receptor, a band was excised and subjected to in-gel tryptic digestion using modified porcine trypsin (Promega) at 20 ng/l. The dried peptides were extracted and analyzed by online nanoLC using an Ultimate 3000 system (Dionex) coupled to an ETD-enabled LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) as described (120, 125) . The survey scan MS was performed in the Orbitrap on the 300 to 2000 m/z mass range with the resolution set to a value of 60.000 at m/z 400. The 20 most intense ions per survey scan were selected for subsequent CID/ETD fragmentation, and the resulting fragments were analyzed in the linear trap (LTQ). The settings for the data-dependent decision tree-based CID/ETD method were as follows: ETD was performed for all precursor ions with charge states >5. The normalized collision energy was set to 35% for CID. The reaction time was set to 100 ms, and supplemental activation was enabled for ETD. Triple technical replicates were performed in some conditions.
All raw MS files were processed with MaxQuant (v 1.5.5.1) for database search with the Andromeda search engine. Data were searched against SwissProt database with taxonomy Mus musculus (16,761 sequences) implemented with the mouse NOP receptor-eGFP sequence. Enzyme specificity was set to trypsin/P, and a maximum of three missed cleavages was allowed. Carbamidomethylation of cysteine was set as fixed modification, whereas oxidation of methionine and phosphorylation of serine, threonine, and tyrosine were set as variable modifications. The precursor mass tolerance was set to 20 parts per million (ppm) for the first search and 10 ppm for the main Andromeda database search. The mass tolerance in MS/MS mode was set to 0.8 Da. The required minimum peptide length was seven amino acids, and the minimum number of unique peptides was set to one. Andromeda results were validated by the target-decoy approach using a reverse database and the false discovery rates at the peptide-spectrum matches; protein and site levels were set to 1%. Phosphosite localization was evaluated on the basis of the Phosphosite Localization Scoring and Localization Probability algorithm of the Andromeda search engine.
Data analysis
Protein bands detected on Western blots were quantified using ImageJ 1.47v software. Data were analyzed using GraphPad Prism 5 software. Densitometry of every protein band was carried out with ImageJ. We used the same area size to perform densitometry for every protein band from the same experiment for every phosphorylation site as well as the total receptor. Accordingly, an equally sized, empty area from the blot/film was measured to subtract this value as background signal from every measuring point. Last, phosphorylation signals were normalized to the total receptor (phosphorylation-independent antibody; NOP receptor). Controls (MOCK or SCR) were defined as 100%, and phosphorylation of every target protein was calculated as percentage phosphorylation in comparison to the respective control. Statistical analysis was carried out with one-way ANOVA followed by Bonferroni correction. P values <0.05 were considered statistically significant.
To compare the ability of different agonists to induce NOP-YFP internalization in primary cultures of ventral midbrain neurons, fluorescent puncta formation was used as a proxy for receptor internalization. This allowed analysis to be performed on images containing several neurons with many of overlapping neurites. It also allowed automated analysis over large numbers of images without the need to manually select regions corresponding to the plasma membrane and cell interior. Puncta identification and counting were performed using Python code that was based on the original approach and MATLAB code developed by Aguet et al. (126) . To quantitatively compare the extent of puncta formation across different conditions, the number of puncta per image was normalized to the total NOP-YFP intensity. The plot shows this "puncta density" for each condition relative to N/OFQ.
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